Author(s): Acquacalda E, Roux CH, Albert C, Breuil V, Passeron T, Euller-Ziegler L
OBJECTIVES: Severe hidradenitis suppurativa (HS), under infliximab, can be associated with different forms of arthritis whose mechanism is unclear. Our objective is to establish the frequency and clinical presentation of new-onset arthritis in HS under infliximab.
METHODS: Severe HS patients under infliximab were followed up between 2007-2012. New articular inflammatory manifestations were investigated by rheumatologist.
RESULTS: Three patients over eleven developed a polyarthritis. Mean duration of arthritis was 3 months. At treatment’s stop: 2 patients improved and 1 relieved with adalimumab.
CONCLUSION: The inflammatory rheumatism’s frequency in HS under infliximab seems underestimated.
Dermatology Journal and/or Publisher
Journal Name: Joint, bone, spine : revue du rhumatisme
Journal Abbreviation: Joint Bone Spine
Journal Date Published: 2015-10-10
National Center for Biotechnology Information
Article Source: http://www.ncbi.nlm.nih.gov/pubmed/25776450
Lasted Revision: 2015-10-10
Abstract Source: National Center for Biotechnology Information, U.S. National Library of Medicine Abstract Query for Hidradenitis suppurativa (HS).